<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04905914</url>
  </required_header>
  <id_info>
    <org_study_id>AR-276-01</org_study_id>
    <nct_id>NCT04905914</nct_id>
  </id_info>
  <brief_title>Study Of ATRN-119 In Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1/2a, Open-Label, Safety, Pharmacokinetic, And Preliminary Efficacy Study Of Oral ATRN-119 In Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atrin Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Atrin Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and effectiveness of ATRN-119 through the&#xD;
      performance of a Phase 1/2a, open-label, safety, PK, and preliminary efficacy study of oral&#xD;
      ATRN-119 in patients with advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 21, 2021</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Emergent Adverse Events (TEAEs) will be collected and evaluated based on summary statistics</measure>
    <time_frame>Day 1 to Day 56</time_frame>
    <description>Treatment-emergent AEs (TEAEs) will be collected and Clinical Laboratory Evaluations will be performed</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>50mg Capsule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>100mg Capsule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>200mg Capsule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>400mg Capsule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>800mg Capsule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATRN-119</intervention_name>
    <description>ATRN-119 is a capsule formulation that will be supplied as 50 mg and 200 mg hydroxymethyl cellulose (HPMC) capsules packed in sealed plastic bottles (n=30) and dispensed by the site pharmacist in combinations to provide the appropriate dose.</description>
    <arm_group_label>100mg Capsule</arm_group_label>
    <arm_group_label>200mg Capsule</arm_group_label>
    <arm_group_label>400mg Capsule</arm_group_label>
    <arm_group_label>50mg Capsule</arm_group_label>
    <arm_group_label>800mg Capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  DNA damage response (DDR) mutations documented in the past medical record or confirmed&#xD;
             during the screening period.&#xD;
&#xD;
          -  Measurable disease defined by RECIST 1.1.&#xD;
&#xD;
          -  Life expectancy â‰¥ 3 months.&#xD;
&#xD;
          -  Subject must be capable of oral administration of study medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has had a cytotoxic chemotherapy, immunotherapy, radiotherapy or other&#xD;
             targeted therapies within 4 weeks.&#xD;
&#xD;
          -  Surgical procedure performed within 7 days prior to first scheduled dose of ATRN-119.&#xD;
&#xD;
          -  Concomitant treatment with strong inhibitors or inducers of CYP3A4 and CYP2D6.&#xD;
&#xD;
          -  Known human immunodeficiency virus infection (HIV).&#xD;
&#xD;
          -  Subjects with active viral or bacterial infections and/or receiving systemic&#xD;
             antibiotics or anti-viral medications.&#xD;
&#xD;
          -  Current or past diagnosis of leukemia within the past 5 years.&#xD;
&#xD;
          -  Prior radiotherapy at the target lesion unless there is evidence of disease&#xD;
             progression.&#xD;
&#xD;
          -  Known CNS metastases or clinical evidence of CNS involvement that is not stable for&#xD;
             previous 1 month by radiology documentation (magnetic resonance imaging [MRI] brain).&#xD;
&#xD;
          -  History of non-malignant gastronintestinal (GI) bleeding, gastric stress ulcerations,&#xD;
             or peptic ulcer disease within the past 3-months.&#xD;
&#xD;
          -  Patient has uncontrolled hypertension at time of enrollment.&#xD;
&#xD;
          -  Complete left bundle branch block (LBBB), bifascicular block (right bundle branch&#xD;
             block [RBBB] with either left anterior hemiblock or left posterior hemiblock).&#xD;
&#xD;
          -  Any clinically significant ST segment and/or T-wave abnormalities.&#xD;
&#xD;
          -  Myocardial infarction or unstable angina pectoris within 6 months prior to starting&#xD;
             study medication.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarina Tanimoto, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Atrin Pharmaceuticals</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Geoffrey Shapiro, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robert Hasson</last_name>
    <phone>619-540-6253</phone>
    <email>rhasson@pacificlinkconsulting.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geoffrey Shapiro, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 17, 2021</study_first_submitted>
  <study_first_submitted_qc>May 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2021</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

